Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Quanta Services Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.48 (market cap $5.07B), while Quanta Services Inc trades at $689.03 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 19.9× ACADIA Pharmaceuticals Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PWR | |
|---|---|---|
Market Cap | $5.07B | $100.82B |
Sector | Health | Industrials |
52-Week High | $29.41 | $785.24 |
52-Week Low | $20.06 | $372.50 |
Enterprise Value | $4.19B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
PWR trades at $660.86, down 1.64% over 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.24 versus $3.31 expected, and raised its full-year 2026 outlook. Revenue growth is robust, reaching $28.48B in 2025, though valuation ratios like a P/E of 76.73 appear elevated. Analyst sentiment is overwhelmingly positive, with 26 buy ratings and a consensus price target of $809.75.
The outlook for PWR is bullish, driven by record backlog and infrastructure demand, but high valuation and negative net cash flow pose risks. Investors face a trade-off between strong growth prospects and premium pricing, with execution on raised guidance being critical for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
